BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11574456)

  • 1. Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes.
    de Luis DA; Aller R; Cuellar L; Terroba C; Ovalle H; Izaola O; Romero E
    Diabetes Care; 2001 Oct; 24(10):1844-5. PubMed ID: 11574456
    [No Abstract]   [Full Text] [Related]  

  • 2. Repaglinide/bedtime NPH insulin is comparable to twice-daily NPH insulin.
    Panelo A; Wing JR;
    Diabetes Care; 2005 Jul; 28(7):1789-90. PubMed ID: 15983336
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents.
    Furlong NJ; Hulme SA; O'Brien SV; Hardy KJ
    Diabet Med; 2003 Nov; 20(11):935-41. PubMed ID: 14632720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy.
    Furlong NJ; Hulme SA; O'Brien SV; Hardy KJ
    Diabetes Care; 2002 Oct; 25(10):1685-90. PubMed ID: 12351462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of repaglinide in combination with metformin and bedtime NPH insulin as an insulin treatment regimen in type 2 diabetes.
    Civera M; Merchante A; Salvador M; Sanz J; Martínez I
    Diabetes Res Clin Pract; 2008 Jan; 79(1):42-7. PubMed ID: 17714824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repaglinide for type 2 diabetes mellitus.
    Med Lett Drugs Ther; 1998 May; 40(1027):55-6. PubMed ID: 9618664
    [No Abstract]   [Full Text] [Related]  

  • 7. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.
    Owens DR; Luzio SD; Ismail I; Bayer T
    Diabetes Care; 2000 Apr; 23(4):518-23. PubMed ID: 10857945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.
    Damsbo P; Clauson P; Marbury TC; Windfeld K
    Diabetes Care; 1999 May; 22(5):789-94. PubMed ID: 10332683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repaglinide.
    Balfour JA; Faulds D
    Drugs Aging; 1998 Aug; 13(2):173-80. PubMed ID: 9739505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.
    Bakiner O; Ertorer ME; Bozkirli E; Tutuncu NB; Demirag NG
    Acta Diabetol; 2009 Mar; 46(1):63-5. PubMed ID: 18825302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of prandial glucose regulation with repaglinide in addressing the problem of hypoglycemia in the treatment of type 2 diabetes.
    Owens D
    J Assoc Physicians India; 2001 Jan; 49 Spec No():54-61. PubMed ID: 11235607
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination therapy in type 2 diabetes: the role of repaglinide.
    Moses R
    J Assoc Physicians India; 2001 Jan; 49 Spec No():62-8. PubMed ID: 11235608
    [No Abstract]   [Full Text] [Related]  

  • 13. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes.
    Moses RG; Gomis R; Frandsen KB; Schlienger JL; Dedov I
    Diabetes Care; 2001 Jan; 24(1):11-5. PubMed ID: 11194214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.
    Raskin P
    Diabetes Obes Metab; 2008 Dec; 10(12):1167-77. PubMed ID: 18494804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.
    Goldberg RB; Einhorn D; Lucas CP; Rendell MS; Damsbo P; Huang WC; Strange P; Brodows RG
    Diabetes Care; 1998 Nov; 21(11):1897-903. PubMed ID: 9802740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control.
    Chisalita SI; Lindström T; Eson Jennersjö P; Paulsson JF; Westermark GT; Olsson AG; Arnqvist HJ
    Acta Diabetol; 2009 Mar; 46(1):35-42. PubMed ID: 18777156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin/Repaglinide (PrandiMet) for type 2 diabetes.
    Med Lett Drugs Ther; 2009 Jun; 51(1313):41-3. PubMed ID: 19478691
    [No Abstract]   [Full Text] [Related]  

  • 18. Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes.
    Damsbo P; Marbury TC; Hatorp V; Clauson P; Müller PG
    Diabetes Res Clin Pract; 1999 Aug; 45(1):31-9. PubMed ID: 10499883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repaglinide in combination therapy.
    Moses R
    Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):33-8. PubMed ID: 12702006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient perceptions of prandial oral therapy for type 2 diabetes.
    Bonneville M; Colgin J; Nalesnick JA; Perez J; Wentz L
    Diabetes Educ; 2001; 27(5):669-77. PubMed ID: 12212016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.